Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2010

View Archived Issues

Takeda reviews first half of fiscal year 2010

Reticulon-4 is a putative biomarker and inducer of pathogenesis in PAH

Tasocitinib leads to sustained improvement in patients with rheumatoid arthritis

First-in-human data presented on RO-5126766 in advanced/metastatic solid tumors

AMG-557 dose-dependently blocks ICOS ligand on B cells in patients with SLE

PA-21 is safe and reduces hyperphosphatemia in subjects with CKD on hemodialysis

AnaptysBio begins to receive QTDP grants in support of four programs

Novo Nordisk reports R&D highlights of third quarter 2010

Boehringer Ingelheim claims new chemokine CXCR3 receptor antagonists

Axikin Pharma presents new chemokine CCR3 receptor antagonists

Institute for OneWorld Health claims new CFTR inhibitors

New oxalato complexes of platinum disclosed for treatment of cancer

Banyu Pharma patents new antagonists of peptide P518 receptor

Vexon divulges new peptide derivatives with analgesic activity

Nostrum Pharma and IMTECH enter license agreement in India for new thrombolytics

Health Canada approves Allergan's Restasis for dry eye disease

FDA clears Auris Medical's IND for phase II AM-101 trial in acute inner ear tinnitus

Auris Medical advances phase IIb trial of AM-111 in acute sensorineural hearing loss

Covidian licenses drug delivery platform technology from UBC and CDRD

Clavis Pharma secures capital to advance anticancer pipeline

FDA extends review period of cladribine tablets for relapsing forms of MS

Basilea and Astellas change primary endpoint for phase III isavuconazole trial in aspergillosis

Verona confirms delivery of RPL-554 by standard asthma inhaler devices

Beech Tree Labs closes financing and receives U.S. government grant

Compugen develops new platform to discover new members of protein families

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 15, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...